These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38014284)
1. The Tsai MM; Chen L; Baumann MH; Canals M; Javitch JA; Lane JR; Shi L bioRxiv; 2023 Nov; ():. PubMed ID: 38014284 [TBL] [Abstract][Full Text] [Related]
2. In Vitro Functional Profiling of Fentanyl and Nitazene Analogs at the μ-Opioid Receptor Reveals High Efficacy for Gi Protein Signaling. Tsai MM; Chen L; Baumann MH; Canals M; Javitch JA; Lane JR; Shi L ACS Chem Neurosci; 2024 Feb; 15(4):854-867. PubMed ID: 38345920 [TBL] [Abstract][Full Text] [Related]
3. Alkoxy chain length governs the potency of 2-benzylbenzimidazole 'nitazene' opioids associated with human overdose. Glatfelter GC; Vandeputte MM; Chen L; Walther D; Tsai MM; Shi L; Stove CP; Baumann MH Psychopharmacology (Berl); 2023 Dec; 240(12):2573-2584. PubMed ID: 37658878 [TBL] [Abstract][Full Text] [Related]
4. Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide. Vandeputte MM; Tsai MM; Chen L; Glatfelter GC; Walther D; Stove CP; Shi L; Baumann MH Drug Alcohol Depend; 2023 Aug; 249():109939. PubMed ID: 37276825 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid. Vandeputte MM; Krotulski AJ; Walther D; Glatfelter GC; Papsun D; Walton SE; Logan BK; Baumann MH; Stove CP Arch Toxicol; 2022 Jun; 96(6):1845-1863. PubMed ID: 35477798 [TBL] [Abstract][Full Text] [Related]
6. Detection of N-desethyl etonitazene in a drug checking sample: Chemical analysis and pharmacological characterization of a recent member of the 2-benzylbenzimidazole "nitazene" class. Monti MC; De Vrieze LM; Vandeputte MM; Persson M; Gréen H; Stove CP; Schlotterbeck G J Pharm Biomed Anal; 2024 Dec; 251():116453. PubMed ID: 39216307 [TBL] [Abstract][Full Text] [Related]
7. Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays. Vandeputte MM; Persson M; Walther D; Vikingsson S; Kronstrand R; Baumann MH; Gréen H; Stove CP Arch Toxicol; 2022 Mar; 96(3):877-897. PubMed ID: 35072756 [TBL] [Abstract][Full Text] [Related]
8. In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances. Vandeputte MM; Cannaert A; Stove CP Arch Toxicol; 2020 Nov; 94(11):3819-3830. PubMed ID: 32734307 [TBL] [Abstract][Full Text] [Related]
9. Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of "Nitazene" 2-Benzylbenzimidazole Synthetic Opioids. Vandeputte MM; Van Uytfanghe K; Layle NK; St Germaine DM; Iula DM; Stove CP ACS Chem Neurosci; 2021 Apr; 12(7):1241-1251. PubMed ID: 33759494 [TBL] [Abstract][Full Text] [Related]
10. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform. Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045 [TBL] [Abstract][Full Text] [Related]
11. First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass. Vandeputte MM; Verougstraete N; Walther D; Glatfelter GC; Malfliet J; Baumann MH; Verstraete AG; Stove CP Arch Toxicol; 2022 Jun; 96(6):1865-1880. PubMed ID: 35449307 [TBL] [Abstract][Full Text] [Related]
12. In vitro structure-activity relationships and forensic case series of emerging 2-benzylbenzimidazole 'nitazene' opioids. De Vrieze LM; Walton SE; Pottie E; Papsun D; Logan BK; Krotulski AJ; Stove CP; Vandeputte MM Arch Toxicol; 2024 Sep; 98(9):2999-3018. PubMed ID: 38877156 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator. Obeng S; Yuan Y; Jali A; Selley DE; Zhang Y Eur J Pharmacol; 2018 May; 827():32-40. PubMed ID: 29530590 [TBL] [Abstract][Full Text] [Related]
14. Tyrosine 7.43 is important for mu-opioid receptor downstream signaling pathways activated by fentanyl. Tian X; Zhang J; Wang S; Gao H; Sun Y; Liu X; Fu W; Tan B; Su R Front Pharmacol; 2022; 13():919325. PubMed ID: 36120357 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a Potent Highly Biased MOR Partial Agonist among Diastereomeric C9-Hydroxyalkyl-5-phenylmorphans. Lutz JA; Sulima A; Gutman ES; Bow EW; Luo D; Kaska S; Prisinzano TE; Paronis CA; Bergman J; Imler GH; Kerr AT; Jacobson AE; Rice KC Molecules; 2023 Jun; 28(12):. PubMed ID: 37375350 [TBL] [Abstract][Full Text] [Related]
16. Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1. Narayan A; Hunkele A; Xu J; Bassoni DL; Pasternak GW; Pan YX Cell Mol Neurobiol; 2021 Jul; 41(5):1059-1074. PubMed ID: 33033993 [TBL] [Abstract][Full Text] [Related]
17. The μ-opioid receptor-mediated G Xia J; Li X; Zhu H; Zhou X; Chen J; Li Q; Li S; Chu H; Dong M Eur J Pharmacol; 2024 Mar; 966():176333. PubMed ID: 38278466 [TBL] [Abstract][Full Text] [Related]
18. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors. Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380 [TBL] [Abstract][Full Text] [Related]
19. In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the β-arrestin2 recruitment assay: No two ligands have the same profile. Kuo A; Magiera J; Rethwan N; Andersson Å; Leen Lam A; Wyse B; Meutermans W; Lewis R; Smith M Eur J Pharmacol; 2020 Apr; 872():172947. PubMed ID: 31991138 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent μ-opioid receptor agonists. De Luca MA; Tocco G; Mostallino R; Laus A; Caria F; Musa A; Pintori N; Ucha M; Poza C; Ambrosio E; Di Chiara G; Castelli MP Neuropharmacology; 2022 Dec; 221():109263. PubMed ID: 36154843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]